Radiotherapy & Oncology
Volume 94, Issue 1 , Pages 42-46 , January 2010

Optimizing dose prescription in stereotactic body radiotherapy for lung tumours using Monte Carlo dose calculation

Received 17 June 2009 ,Revised 27 October 2009 ,Accepted 29 November 2009.

Reference 

  1. Wulf J, Baier K, Mueller G, Flentje M. Dose–response in stereotactic irradiation of lung tumors. Radiother Oncol. 2005;77:83–87
  2. Timmerman RD, Park C, Kavanagh BD. The North American experience with stereotactic body radiation therapy in non-small cell lung cancer. J Thorac Oncol. 2007;2:S101–S112
  3. Lagerwaard FJ, Haasbeek CJ, Smit EF, Slotman BJ, Senan S. Outcomes of risk-adapted fractionated stereotactic radiotherapy for stage I non-small-cell lung cancer. Int J Radiat Oncol Biol Phys. 2008;70:685–692
  4. Chang JY, Balter PA, Dong L, Yang Q, Liao Z, Jeter M, et al. Stereotactic body radiation therapy in centrally and superiorly located stage I or isolated recurrent non-small-cell lung cancer. Int J Radiat Oncol Biol Phys. 2008;72:967–971
  5. Brock J, Ashley S, Bedford J, Nioutsikou E, Partridge M, Brada M. Review of hypofractionated small volume radiotherapy for early-stage non-small cell lung cancer. Clin Oncol (R Coll Radiol). 2008;20:666–676
  6. Haasbeek CJ, Senan S, Smit EF, Paul MA, Slotman BJ, Lagerwaard FJ. Critical review of nonsurgical treatment options for stage I non-small cell lung cancer. Oncologist. 2008;13:309–319
  7. Potters L, Steinberg M, Rose C, Timmerman R, Ryu S, Hevezi JM, et al. American Society for Therapeutic Radiology and Oncology and American College of Radiology practice guideline for the performance of stereotactic body radiation therapy. Int J Radiat Oncol Biol Phys. 2004;60:1026–1032
  8. Underberg RW, Lagerwaard FJ, Cuijpers JP, Slotman BJ, van Sornsen de Koste JR, Senan S. Four-dimensional CT scans for treatment planning in stereotactic radiotherapy for stage I lung cancer. Int J Radiat Oncol Biol Phys. 2004;60:1283–1290
  9. Underberg RW, Lagerwaard FJ, Slotman BJ, Cuijpers JP, Senan S. Benefit of respiration-gated stereotactic radiotherapy for stage I lung cancer: an analysis of 4DCT datasets. Int J Radiat Oncol Biol Phys. 2005;62:554–560
  10. Underberg RW, Lagerwaard FJ, Slotman BJ, Cuijpers JP, Senan S. Use of maximum intensity projections (MIP) for target volume generation in 4DCT scans for lung cancer. Int J Radiat Oncol Biol Phys. 2005;63:253–260
  11. Blomgren H, Lax I, Naslund I, Svanstrom R. Stereotactic high dose fraction radiation therapy of extracranial tumors using an accelerator. Clinical experience of the first thirty-one patients. Acta Oncol. 1995;34:861–870
  12. Cardinale RM, Wu Q, Benedict SH, Kavanagh BD, Bump E, Mohan R. Determining the optimal block margin on the planning target volume for extracranial stereotactic radiotherapy. Int J Radiat Oncol Biol Phys. 1999;45:515–520
  13. ICRU report 62 prescribing, recording and reporting photon beam therapy. Supplement to ICRU report 50 33, 1–51; 1999.
  14. McGarry RC, Papiez L, Williams M, Whitford T, Timmerman RD. Stereotactic body radiation therapy of early-stage non-small-cell lung carcinoma: phase I study. Int J Radiat Oncol Biol Phys. 2005;63:1010–1015
  15. Arvidson NB, Mehta MP, Tome WA. Dose coverage beyond the gross tumor volume for various stereotactic body radiotherapy planning techniques reporting similar control rates for stage I non-small-cell lung cancer. Int J Radiat Oncol Biol Phys. 2008;72:1597–1603
  16. Jin L, Wang L, Li J, Luo W, Feigenberg SJ, Ma CM. Investigation of optimal beam margins for stereotactic radiotherapy of lung-cancer using Monte Carlo dose calculations. Phys Med Biol. 2007;52:3549–3561
  17. Nuyttens JJ, Prevost JB, Praag J, Hoogeman M, Van Klaveren RJ, Levendag PC, et al. Lung tumor tracking during stereotactic radiotherapy treatment with the CyberKnife: marker placement and early results. Acta Oncol. 2006;45:961–965
  18. Lax I, Blomgren H, Naslund I, Svanstrom R. Stereotactic radiotherapy of malignancies in the abdomen. Methodological aspects. Acta Oncol. 1994;33:677–683
  19. Hurkmans CW, Cuijpers JP, Lagerwaard FJ, Widder J, van der Heide UA, Schuring D, et al Radiat Oncol. 2009;4:1
  20. Onishi H, Araki T, Shirato H, Nagata Y, Hiraoka M, Gomi K, et al. Stereotactic hypofractionated high-dose irradiation for stage I nonsmall cell lung carcinoma: clinical outcomes in 245 subjects in a Japanese multiinstitutional study. Cancer. 2004;101:1623–1631
  21. Takayama K, Nagata Y, Negoro Y, Mizowaki T, Sakamoto T, Sakamoto M, et al. Treatment planning of stereotactic radiotherapy for solitary lung tumor. Int J Radiat Oncol Biol Phys. 2005;61:1565–1571
  22. Timmerman R, Papiez L, McGarry R, Likes L, DesRosiers C, Frost S, et al. Extracranial stereotactic radioablation: results of a phase I study in medically inoperable stage I non-small cell lung cancer. Chest. 2003;124:1946–1955
  23. Baumann P, Nyman J, Lax I, Friesland S, Hoyer M, Rehn Ericsson S, et al. Factors important for efficacy of stereotactic body radiotherapy of medically inoperable stage I lung cancer. A retrospective analysis of patients treated in the Nordic countries. Acta Oncol. 2006;45:787–795
  24. Baumann P, Nyman J, Hoyer M, Gagliardi G, Lax I, Wennberg B, et al. Stereotactic body radiotherapy for medically inoperable patients with stage I non-small cell lung cancer – a first report of toxicity related to COPD/CVD in a non-randomized prospective phase II study. Radiother Oncol. 2008;88:359–367
  25. Cormack AM. A problem in rotation therapy with X-rays. Int J Radiat Oncol Biol Phys. 1987;13:623–630
  26. Lax I. Target dose versus extratarget dose in stereotactic radiosurgery. Acta Oncol. 1993;32:453–457
  27. Tulovsky V, Ringor M, Papiez L. Optimization of rotational radiotherapy treatment planning. Int J Radiat Oncol Biol Phys. 1995;32:1205–1214
  28. Papiez L, Timmerman R, DesRosiers C, Randall M. Extracranial stereotactic radioablation: physical principles. Acta Oncol. 2003;42:882–894
  29. Xiao Y, Papiez L, Paulus R, Timmerman R, Straube WL, Bosch WR, et al. Dosimetric evaluation of heterogeneity corrections for RTOG 0236: stereotactic body radiotherapy of inoperable stage I–II non-small-cell lung cancer. Int J Radiat Oncol Biol Phys. 2009;73:1235–1242
  30. Schuring D, Hurkmans CW. Developing and evaluating stereotactic lung RT trials: what we should know about the influence of inhomogeneity corrections on dose. Radiat Oncol. 2008;3:21
  31. van der Laan HP, Dolsma WV, Maduro JH, Korevaar EW, Hollander M, Langendijk JA. Three-dimensional conformal simultaneously integrated boost technique for breast-conserving radiotherapy. Int J Radiat Oncol Biol Phys. 2007;68:1018–1023

PII: S0167-8140(09)00647-1

doi: 10.1016/j.radonc.2009.11.008

Radiotherapy & Oncology
Volume 94, Issue 1 , Pages 42-46 , January 2010

Article Tools

* Image Usage & Resolution